Targeting Tumour Necrosis Factor in the Treatment of Rheumatoid Arthritis

ISSN： 1173-8804

Source： BioDrugs, Vol.15, Iss.3, 2001-03, pp. : 139-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumour Necrosis Factor- Blockers in Rheumatoid Arthritis: Review of the Clinical Experience

By Richard-Miceli C. Dougados M.

BioDrugs, Vol. 15, Iss. 4, 2001-04 ,pp. : 251-259

Adis International

Access to resources Recommend Favorite

Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis: Focus on the Soluble TNF Receptor p75 Fusion Protein, Etanercept

By Moreland L.W.

BioDrugs, Vol. 11, Iss. 3, 1999-03 ,pp. : 201-210

Adis International

Access to resources Recommend Favorite

Side effects of cancer treatment with recombinant human tumour necrosis factor alpha: a new challenge for the intensive care unit

By ZWAVELING J H MARING J K GIRIBES A R J KOOPS H SCHRAFFORDT

Clinical Intensive Care, Vol. 8, Iss. 3, 1997-06 ,pp. : 142-150

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Golimumab: In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

By Oldfield Vicki Plosker Greg L.

BioDrugs, Vol. 23, Iss. 2, 2009-06 ,pp. : 125-135

Adis International

Access to resources Recommend Favorite

Regional Administration of Recombinant Tumour Necrosis Factor- in Cancer, with Special Reference to Melanoma

By Lejeune F.

BioDrugs, Vol. 9, Iss. 3, 1998-03 ,pp. : 211-218

Adis International

Access to resources Recommend Favorite